发明名称 |
Pharmaceutical formulation containing gelling agent |
摘要 |
Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient. |
申请公布号 |
US9060976(B2) |
申请公布日期 |
2015.06.23 |
申请号 |
US201213726324 |
申请日期 |
2012.12.24 |
申请人 |
Purdue Pharma L.P.;The P.F. Laboratories, Inc.;Purdue Pharmaceuticals L.P. |
发明人 |
Wright Curtis;Oshlack Benjamin;Breder Christopher |
分类号 |
A61K31/439;A61K31/485;A61K31/167;A61K9/20;A61K9/00;A61K47/38;A61K47/36;A61K47/10;A61K45/06 |
主分类号 |
A61K31/439 |
代理机构 |
Lowenstein Sandler LLP |
代理人 |
Lowenstein Sandler LLP |
主权项 |
1. An extended release abuse deterrent dosage form comprising:
a. a core matrix comprising a blended mixture of:
(a) PEO having a molecular weight of from about 300,000 daltons to about 5,000,000 daltons;(b) magnesium stearate; and(c) oxycodone or a pharmaceutically acceptable salt thereof; wherein the core matrix is heated to melt at least a portion of the PEO included in the core matrix during preparation of the dosage form; and b. PEG applied onto the core matrix; wherein the dosage form provides extended release of the drug. |
地址 |
Stamford CT US |